RSV Policy Statement —Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics 2014;134(2):415–420
An error occurred in the policy statement from the American Academy of Pediatrics titled “Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection” published in the August 2014 issue of Pediatrics (2014;134:415–420). On pages 417–418, the last sentence in the section titled Use of Palivizumab in the Second Year of Life should read: “A second season of palivizumab prophylaxis is recommended only for preterm infants born at <32 weeks, 0 days’ gestation who required at least 28 days of oxygen after birth and who continue to require supplemental oxygen, chronic systemic corticosteroid therapy, or diuretic therapy within 6 months of the start of the second RSV season.” Bronchodilator therapy has been removed as a consideration for prophylaxis in the second RSV season.
We regret this error.
- Copyright © 2014 by the American Academy of Pediatrics